Eli Lilly and Company (NYSE:LLY) Trading 3.7% Higher After Analyst Upgrade

Eli Lilly and Company (NYSE:LLY)’s share price was up 3.7% during trading on Monday after Truist Financial raised their price target on the stock from $1,370.00 to $1,376.00. Truist Financial currently has a buy rating on the stock. Eli Lilly and Company traded as high as $1,231.94 and last traded at $1,230.00. Approximately 2,922,758 shares traded hands during mid-day trading, a decline of 7% from the average session volume of 3,142,988 shares. The stock had previously closed at $1,185.71.

LLY has been the subject of several other research reports. The Goldman Sachs Group restated a “buy” rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a research note on Thursday. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Finally, UBS Group upped their price target on shares of Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,292.18.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Blowout Q2 results and raised outlook: Lilly reported $22.97 billion in second-quarter revenue, up 47.7% year over year and above the $20.82 billion consensus estimate. Adjusted earnings of $8.38 per share also exceeded expectations by $1.98. Management raised its full-year targets, reinforcing expectations for sustained growth from Mounjaro and Zepbound. Why Did Eli Lilly Jump After Its Latest Quarterly Report?
• Positive Sentiment: Oral obesity drug could expand the market: Investor optimism is also focused on Lilly’s next-generation obesity pill. Broader prescribing access and potential insurance coverage could make an oral treatment an important growth catalyst alongside the company’s injectable GLP-1 medicines. Eli Lilly Stock’s Next Climb Runs Through a Pill
• Positive Sentiment: Competitive position in obesity drugs: Analysts continue to view Lilly as a leading GLP-1 provider, with a deep pipeline and strong commercial momentum. A more cautious outlook for rival Novo Nordisk highlights Lilly’s current competitive advantage. Novo Nordisk Stock Plunges Amid Eli Lilly Rivalry
• Positive Sentiment: Pipeline diversification: Lilly’s olomorasib received FDA Breakthrough Therapy designation for certain advanced pancreatic cancer patients, while a collaboration will evaluate the drug in lung cancer. The developments support efforts to broaden growth beyond diabetes and obesity. Eli Lilly Gains FDA Breakthrough Nod
• Neutral Sentiment: Lilly participated in Remedium Bio’s $10 million Series A financing, offering potential long-term pipeline exposure but little immediate earnings impact. Lifespan Vision Ventures Leads Remedium Bio Financing
• Negative Sentiment: The stock is trading near its 52-week high at a premium valuation, leaving less room for execution disappointments, regulatory setbacks or intensifying competition in the GLP-1 market.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $12,976,634,000. J. Stern & Co. LLP grew its holdings in shares of Eli Lilly and Company by 46,191.3% during the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after purchasing an additional 4,038,502 shares during the last quarter. Cardano Risk Management B.V. raised its position in Eli Lilly and Company by 876.1% in the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock worth $2,552,419,000 after purchasing an additional 2,131,734 shares during the period. Fifth Third Bancorp lifted its stake in Eli Lilly and Company by 321.3% in the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after purchasing an additional 1,497,423 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Eli Lilly and Company by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock valued at $16,024,022,000 after buying an additional 1,432,069 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 3.7%

The stock has a market capitalization of $1.16 trillion, a P/E ratio of 41.28, a PEG ratio of 1.38 and a beta of 0.51. The stock has a 50 day moving average price of $1,159.38 and a 200-day moving average price of $1,047.62. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.Eli Lilly and Company’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the business posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts expect that Eli Lilly and Company will post 36.77 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 23.22%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.